ubenimex

ubenimex

Alternative oncology
A competitive protease-inhibiting peptide isolated from the supernatant broth of cultured Streptomyces olivoreticuli that inhibits aminopeptidases B and N and leukotriene A4 hydrolase. Ubenimex stimulates the immune system, activates macrophages, increases production and secretion of IL-1 and IL-2, and stimulates T cells and haematopoiesis. It is in clinical trials for acute myeloid leukaemia and may be effective in treating various cancers, including Hodgkin lymphoma, leukaemia, melanoma, and cancers of the bladder, oesophagus, head and neck, lung and stomach.
Mentioned in ?
References in periodicals archive ?
today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug status to ubenimex for the treatment of pulmonary arterial hypertension (PAH).
We are pleased with the OOPD's designation of orphan drug status for ubenimex in PAH.
Ubenimex is approved in Japan as an adjunct to chemotherapy agents to extend survival and to maintain remission after treatment for acute non-lymphocytic leukemia in adults.
Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary Arterial Hypertension

Medical browser ?
Full browser ?